Medivation Shares up 140% On Positive MDV3100 Results
BioWorld Today Contributing Writer
Medivation Inc. stock doubled and then some following an announcement by the San Francisco-based biotech and partner Astellas Pharma Inc., of Tokyo, that results from an interim analysis of the Phase III AFFIRM trial of MDV3100 in men with advanced prostate cancer were so positive that the independent data monitoring committee recommended the trial be stopped and MDV3100 offered to the men who received placebo.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST